EXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug Approval

Pharmaceutical firm Sunshine Biopharma Inc. (NASDAQ:SBFM) connected Tuesday said it received regulatory support to present its 2mg generic Dienogest tablets to the Canadian market.

The important milestone marks the company's strategical enlargement into women's healthcare, specifically targeting first-line therapy for pelvic symptom associated with endometriosis.

Read Also:Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin

The generic medicine drugs shaper successful June implemented a one-for-ten reverse banal split.

Expanding Into Women's Health Sector

Dienogest serves arsenic the nonstop generic equivalent to the brand-name medication, Visanne.

The therapeutic tablet functions by attaching to progesterone receptors, delivering localized anti-inflammatory benefits, and mildly suppressing hormones.

Through these targeted mechanisms of action, the medicine efficaciously alleviates terrible endometriosis-related discomfort by actively shrinking the maturation of abnormal tissue.

The women's wellness merchandise volition beryllium distributed exclusively via Nora Pharma Inc., the company's wholly owned Canadian subsidiary.

Nora Pharma has already established a organisation network.

Management anticipates that the recently approved generic Dienogest volition beryllium afloat acceptable to vessel straight to Canadian retail pharmacies by the extremity of 2026.

Capturing Rapidly Growing Global Market

The economical prospects for this therapy are substantial. Based connected manufacture projections provided by Dataintelo, the worldwide marketplace for Dienogest medications was valued astatine $2.8 cardinal successful 2025.

The assemblage is projected to grow astatine a compound yearly maturation complaint (CAGR) of 7.8%, perchance reaching an wide marketplace valuation of $5.2 cardinal by 2034.

According to statistic from IQVIA Pharmafocus 2028, the Canadian pharmaceutical manufacture is presently ranked arsenic the sixth-largest globally.

The federation accounts for astir 2.1% of the full planetary pharmaceutical market.

In July, Canada approved Sunshine Biopharma's generic Ondansetron tablets of 4mg and 8mg. Ondansetron is the generic equivalent of the marque sanction Zofran.

Ondansetron is highly prescribed for nausea and vomiting caused by crab chemotherapy, radiation therapy, and surgery.

SBFM Price Action: Sunshine Biopharma shares were up 6.84% astatine $1.25 during premarket trading connected Tuesday. The banal is trading adjacent its 52-week debased of $1.10, according to Benzinga Pro data.

Read Also:Will PLTR Surge Past $150 successful August? Crypto Punters Raise the Stakes After Palantir's Solid Q2 Earnings